SynOcu™ Cornea-on-a-Chip
Human-Relevant Model for Corneal Drug Transport, Safety & Efficacy Under Physiological Flow
SynOcu Cornea-on-a-Chip
SynOcu™ is a dynamic, microfluidic Cornea-on-a-Chip platform designed to mimic native human corneal architecture and barrier function. Using physiologically realistic flow, SynOcu enables direct, real-time visualization of drug transport across the corneal layers—making it ideal for ophthalmic drug development, delivery optimization, and safety studies.
Key Features:
- Tri-culture of epithelial, stromal, and endothelial cells
- Real-time flow-based modeling of tear film and aqueous humor
- Modularity to add conjunctiva and simulate dual delivery routes
- Maintains native phenotype with validated morphology & marker expression
- Compatible with imaging and high-content readouts
Applications:
- Drug permeability & transport assays
- Antibody-drug conjugate (ADC) ocular toxicity
- Safety pharmacology & cytotoxicity
- Ophthalmic formulation optimization
- Nanoparticle drug delivery
Why SynOcu™ Outperforms Traditional Models
- Dynamic flow mimics tear and aqueous humor
- Human cell-based, animal-free design
- Tri-layer complexity in a single chip
- Imaging-compatible and automation-ready
- Expandable to conjunctiva and other ocular tissue
Cornea-on-a-Chip Model Characterization
Performance That Mirrors Human Physiology
Marker Expression
CK3 stratification marker increases under flow supporting epithelial maturation.
Barrier Integrity
Small molecule permeability significantly decreases from mono- to tri-culture, mimicking in vivo tight junctions.
Physiological Transport
SynOcu’s flow-based model more closely mimics paracellular transport in human tissue than static Transwell inserts.
Contact our scientists to find out how SynOcu™ can accelerate your drug development with human-relevant data.
Contract Research Services
SynOcu™ Cornea-on-a-Chip: Comprehensive Services for Ocular Drug Development
SynVivo offers expert-led contract research services (CRO) leveraging the SynOcu™ platform for advanced ocular drug development. Our team supports end-to-end study design, execution, and analysis to meet your safety, efficacy, and delivery objectives without the limitations of animal models.
Examples of Services Offering
- Drug Transport
- Quantitative assessment of ocular permeability
- Evaluate drug penetration across human-relevant corneal barrier
- Drug Safety
- Detection of cytotoxicity and barrier integrity loss
- Early-stage safety profiling of small molecules, biologics, and ADCs
- Drug Efficacy
- Measure therapeutic effect on inflamed or injured corneal models
- Support for proof-of-concept and comparative studies
- ADC Testing
- Specific evaluation of antibody-drug conjugates for ocular toxicity and transport
- Identify corneal safety risks of targeted therapies